At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen Lachmann, MA, MB BChir, MD, FRCP, from the Royal Free London NHS Foundation Trust, London, UK discusses the results of a trial which analysed the use of canakinumab to treat tumour necrosis factor receptor-associated periodic syndrome (TRAPS), and how they relate to her own experiences in the UK.
Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)
19th April 2016
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally